Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
India (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      Anti-Human HLA-DR FITC/CD13 PE

      BD Oncomark™ Anti-Human HLA-DR FITC/CD13 PE

      (RUO (GMP))
      Product Details
      Down Arrow Up Arrow


      BD Oncomark™
      Human
      Flow cytometry
      RUO (GMP)
      Phosphate buffered saline with gelatin and 0.1% sodium azide.


      Description

      Anti–HLA-DR, clone L243, is derived from the hybridization of mouse NS-1/1-Ag4 myeloma cells with spleen cells from BALB/c mice immunized with the human lymphoblastoid B-cell line RPMI 8866.

      CD13, clone L138, is derived from hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c x C57BL16 hybrid mice immunized with the KG-1a cell line.

      Anti–HLA-DR recognizes a human class II major histocompatibility complex (MHC) antigen. The antigen is a transmembrane glycoprotein composed of α and β subunits that have molecular weights of 36 and 27 kilodaltons (kd), respectively.

      The CD13 antibody recognizes aminopeptidase N, a 150- to 170-kd single-chain integral membrane glycoprotein.

      Preparation And Storage

      Store vials at 2–8°C. Do not freeze reagents; protect them from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

      Show More blue down arrow Show Less blue up arrow
      341144 Rev. 1
      Components
      Down Arrow Up Arrow
      Description Clone Isotype EntrezGene ID
      CD13 PE L138 IgG1, κ 290
      Anti-HLA DR FITC L243 IgG2a, κ N/A
      341144 Rev. 1
      Citations & References
      Down Arrow Up Arrow

      Development References (28)

      1. Borowitz MJ, Gockerman JP, Moore JO, et al. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol. 1989; 91:265-270. (Biology).
      2. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis, Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol. 1993; 100:534-540. (Biology).
      3. Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.. Immunogenetics. 1984; 19(3):179-94. (Biology). View Reference
      4. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression.. J Immunol. 1986; 137(2):490-7. (Biology). View Reference
      5. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody.. Proc Natl Acad Sci USA. 1981; 78(3):1791-5. (Biology). View Reference
      6. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Biology). View Reference
      7. Gadd S. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:782-784.
      8. Greaves MF, Chan LC, Furley AJW, Watt SM, Molgaard HV. Lineage promiscuity in hematopoietic differentiation and leukemia. Blood. 1986; 67:43841. (Biology).
      9. Greaves MF, Hariri G, Newman RA, Sutherland DR, Ritter MA, Ritz J. Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood. 1983; 61:628-639. (Biology).
      10. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol. 1998; 102(4):1035-1041. (Biology).
      11. Hurwitz CA, Loken MR, Graham ML, et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.. Blood. 1988; 72(1):299-307. (Biology). View Reference
      12. Lacombe F, Durrieu F, Briais A, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 1997; 11:1878-1886. (Biology).
      13. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line.. J Immunol. 1980; 125(1):293-9. (Biology). View Reference
      14. Levacher M, Tallet S, Dazza MC, Dournon E, Rouveix B, Pocidalo JJ. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.. Clin Exp Immunol. 1990; 81(2):177-82. (Biology). View Reference
      15. Look AT, Ashmun RA, Shapiro LH, et al. Report on the CD13 (aminopeptidase N) cluster Workshop. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:784-787.
      16. Macedo A, Orfao A, Vidriales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol. 1995; 70(4):189-194. (Biology).
      17. Paietta E, Andersen J, Gallagher R, et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994; 8:1108-1112. (Biology).
      18. Porwit-MacDonald A, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry, IV: CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood. 1996; 87:1162-1169. (Biology).
      19. Rainer RO, Hodges L, Seltzer GT. CD 45 gating correlates with bone marrow differential. Cytometry. 1995; 22(2):139-145. (Biology).
      20. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Biology). View Reference
      21. Sun T, Sangaline R, Ryder J, et al. Gating strategy for immunophenotyping of leukemia and lymphoma. Am J Clin Pathol. 1997; 108(2):152-157. (Biology).
      22. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Biology). View Reference
      23. Terstappen LW, Safford M, Könemann S, et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.. Leukemia. 1992; 6(1):70-80. (Biology). View Reference
      24. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection.. J Immunol. 1987; 139(11):3802-7. (Biology). View Reference
      25. Vaughan WP, Civin CI, Weisenburger DD, et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia. 1988; 2:661-666. (Biology).
      26. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma.. N Engl J Med. 1980; 303(6):293-300. (Biology). View Reference
      27. Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotinavidin-horseradish peroxidase method. J Histochem Cytochem. 1980; 28:771-776. (Biology).
      28. Zipf RF, Fox R, Dilley J, Levy R. Definition of the high risk ALL patient by immunologic phenotyping withmonoclonal antibodies. Cancer Res. 1981; 41:4786. (Biology).
      View All (28) View Less
      341144 Rev. 1

      Please refer to Support Documents for Quality Certificates

      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures. 

       

      Although not required, these products are manufactured in accordance with Good Manufacturing Practices.

      Website Feedback